Morning vs. evening dosing for metastatic breast or prostate cancer
Part of Cancer, Kidney & urinary, Skin clinical trials.
This trial tests whether taking your hormone therapy and targeted pills in the morning or evening affects how well they work and how you feel. It is for people with metastatic breast or prostate cancer starting a specific hormone-based treatment combination.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic (spread) breast cancer that is hormone receptor-positive, or metastatic prostate cancer that still responds to hormone therapy.
- You are about to start a new treatment: for breast cancer, this is an aromatase inhibitor or similar plus a CDK4/6 inhibitor (Ribociclib or Palbociclib). For prostate cancer, this is an AR pathway inhibitor (Enzalutamide, Apalutamide, or Abiraterone) plus hormone deprivation therapy.
- You are 18 years or older.
- You can give verbal consent and are willing to fill out questionnaires during the study.
- You are not planning to take a medication that requires twice-a-day dosing (like Abemaciclib for breast cancer or Darolutamide for prostate cancer).
- For prostate cancer only: You are not planning to get chemotherapy (Docetaxel) along with your hormone treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two targeted therapy drugs, palbociclib and ribociclib, combined with hormone therapy for people aged 60 or older with hormone receptor-positive, HER2-negative metastatic breast cancer. The goal is to see how well this treatment works and to gather information that may help improve dosing for older adults.
This trial is testing whether adjusting the dose of a targeted therapy (CDK 4/6 inhibitor) based on a geriatric assessment can be as effective and safer for people aged 70 and older with advanced hormone receptor-positive, HER2-negative breast cancer. It aims to find the best dose to balance benefits and side effects.
This study tests several new drug combinations for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to find better ways to control the disease and improve outcomes.
This study tests different ways of giving hormone therapy to find the right dose for men with prostate cancer that has spread. It aims to help manage the disease while limiting side effects.
This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.
This study is looking at how well people stick to a treatment plan that combines hormone therapy with a pill called a CDK4/6 inhibitor after surgery for early-stage breast cancer. The goal is to learn more about adherence so doctors can help patients stay on track.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.